EYPT vs. TXG, TRNS, SENS, CTKB, LAB, ALNT, AEHR, QTRX, QSI, and NAUT
Should you be buying EyePoint Pharmaceuticals stock or one of its competitors? The main competitors of EyePoint Pharmaceuticals include 10x Genomics (TXG), Transcat (TRNS), Senseonics (SENS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Allient (ALNT), Aehr Test Systems (AEHR), Quanterix (QTRX), Quantum-Si (QSI), and Nautilus Biotechnology (NAUT). These companies are all part of the "measuring and control equipment" industry.
EyePoint Pharmaceuticals vs.
EyePoint Pharmaceuticals (NASDAQ:EYPT) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.
EyePoint Pharmaceuticals has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.
In the previous week, 10x Genomics had 38 more articles in the media than EyePoint Pharmaceuticals. MarketBeat recorded 40 mentions for 10x Genomics and 2 mentions for EyePoint Pharmaceuticals. EyePoint Pharmaceuticals' average media sentiment score of 0.34 beat 10x Genomics' score of -0.08 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the media.
EyePoint Pharmaceuticals has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
10x Genomics has a net margin of -29.90% compared to EyePoint Pharmaceuticals' net margin of -226.57%. 10x Genomics' return on equity of -25.40% beat EyePoint Pharmaceuticals' return on equity.
99.4% of EyePoint Pharmaceuticals shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 4.7% of EyePoint Pharmaceuticals shares are held by insiders. Comparatively, 10.0% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
EyePoint Pharmaceuticals currently has a consensus target price of $26.63, suggesting a potential upside of 319.29%. 10x Genomics has a consensus target price of $20.57, suggesting a potential upside of 77.95%. Given EyePoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe EyePoint Pharmaceuticals is more favorable than 10x Genomics.
EyePoint Pharmaceuticals received 406 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 70.29% of users gave EyePoint Pharmaceuticals an outperform vote while only 51.72% of users gave 10x Genomics an outperform vote.
Summary
EyePoint Pharmaceuticals beats 10x Genomics on 10 of the 18 factors compared between the two stocks.
Get EyePoint Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EyePoint Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:EYPT) was last updated on 2/20/2025 by MarketBeat.com Staff
